API
< Back to all clusters
[HEALTH] · India · 13 sources

started · updated

India caps trade margins on 137 anti-cancer drugs to reduce costs

The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30 percent for 137 non-scheduled anti-cancer medicines in India. This regulatory move, based on recommendations from an expert committee under the Directorate General of Health Services, is set to take effect on November 9.

According to the Ministry of Chemicals and Fertilizers, the price reductions are expected to save consumers approximately Rs 3,502.31 crore annually. So far, 76 pharmaceutical companies have reported revised maximum retail prices (MRPs) for 1,225 formulations covering 121 drugs. Of these, 1,031 formulations show price decreases, with 600 brands seeing reductions of over 50 percent. The highest recorded price cut is 96.45 percent.

Significant price drops include Zydus Lifesciences’ Bryxta, which fell from Rs 25,995 to Rs 3,318, and Arvincare Pharma’s ABIRONE, which dropped from Rs 41,250 to Rs 3,218.23. The government noted that the Trade Margin Rationalization (TMR) will also apply to 10 to 15 identified drugs that have not yet been launched in the Indian market.

Retailers, hospitals, and medical institutions are required to prominently display the revised MRP lists. State drug controllers will monitor compliance to ensure the benefits reach patients.

Entities

Directorate General of Health Services · India · Ministry of Chemicals and Fertilizers · Ministry of Health and Family Welfare · National Pharmaceutical Pricing Authority · Zydus Lifesciences

Claims

What the coverage asserts, and how many sources carry each claim.

Sources